Get the Stockscreener App
47.90
0.05%
-0.0017
Royalty Pharma Plc stock is traded at $47.90, with a volume of 1.19M.
It is down -0.05% in the last 24 hours and up +4.88% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$47.90
Open:
$47.87
24h Volume:
1.19M
Relative Volume:
0.34
Market Cap:
$20.52B
Revenue:
$2.38B
Net Income/Loss:
$1.32B
P/E Ratio:
26.90
EPS:
1.7806
Net Cash Flow:
$897.24M
1W Performance:
+1.17%
1M Performance:
+4.88%
6M Performance:
+35.09%
1Y Performance:
+49.85%
1-Day Range:
$47.81
$48.72
1-Week Range:
$46.53
$48.72
52-Week Range:
$31.58
$49.06
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
47.89 | 20.52B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
439.79 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
739.63 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
806.49 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.47 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.26 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma funds additional $250M after Phase 3 win for daraxonrasib in metastatic PDAC - TradingView — Track All Markets
Royalty Pharma (NASDAQ: RPRX) deepens $2B daraxonrasib royalty and loan pact - Stock Titan
Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6% - Insider Monkey
Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Technical Reactions to RPRX Trends in Macro Strategies - Stock Traders Daily
Trend Review: Does Royalty Pharma plc have high return on assetsForecast Cut & Fast Exit and Entry Trade Guides - baoquankhu1.vn
[ARS] Royalty Pharma plc SEC Filing - Stock Titan
[DEF 14A] Royalty Pharma plc Definitive Proxy Statement - Stock Titan
Today's Analyst Rating Update for Royalty Pharma (RPRX) | RPRX S - GuruFocus
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Assessing Royalty Pharma (RPRX) Valuation After Johnson & Johnson Autoimmune Co Funding Deal - Sahm
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
Does J&J Co-Funding Deal Around Dual-Pathway Autoimmune Candidate Recast The Bull Case For Royalty Pharma (RPRX)? - Sahm
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest - Barchart.com
Volume Summary: Can Royalty Pharma plc scale operations efficiently2026 Highlights & Capital Protection Trading Alerts - baoquankhu1.vn
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighHere's What Happened - MarketBeat
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc deliver consistent dividends2026 Outlook & Breakout Confirmation Trade Signals - baoquankhu1.vn
RPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
RPRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Royalty Pharma Leans Into R&D And AI To Shape Future Royalties - Sahm
Royalty Pharma Plc Hits New 52-Week High at $48.74 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - marketbeat.com
Royalty Pharma (RPRX) CFO-linked entities execute planned share sales - Stock Titan
Royalty Pharma plc (RPRX) latest stock news and headlines - Yahoo Finance Singapore
Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal - Yahoo Finance UK
Multiple RPRX Share Disposals by TPC RP Entities (RPRX) - Stock Titan
Pablo Legorreta: Pioneer of Pharmaceutical Royalties, Financial Innovator, and Founder and CEO of Royalty Pharma - BBN Times
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - The Manila Times
J. Safra Sarasin Holding AG Purchases Shares of 90,035 Royalty Pharma PLC $RPRX - MarketBeat
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Royalty Pharma stock hits 52-week high at $47.87 By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (RPRX) director granted 815-share equity award - Stock Titan
Royalty Pharma stock hits 52-week high at $47.87 - Investing.com
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
TD Cowen reiterates Royalty Pharma stock Buy rating on lupus drug potential By Investing.com - za.investing.com
Royalty Pharma and J&J partner to develop autoimmune treatment - Yahoo Finance
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Royalty Pharma in $500M R&D funding collaboration with J&J - MSN
Royalty Pharma commits $500M to J&J autoimmune drug development By Investing.com - Investing.com Canada
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases - 富途牛牛
Royalty Pharma commits $500M to J&J autoimmune drug development - Investing.com
Johnson & Johnson taps Royalty Pharma for $500M autoimmune drug push - Stock Titan
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Refreshes Leadership As AI And Asia Shape Valuation Story - Yahoo Finance
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):